Pancreatic Cancer Research

ResearcherSanofi (France)Active in the last 2 years

Uwe Pelzer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9213-2737; OpenAlex author ID A5006886614. Sources: OpenAlex.

Their work

Papers
69 (first author 5, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
163
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 4 papers · 2014: 7 papers · 2015: 5 papers · 2016: 4 papers · 2017: 4 papers · 2018: 6 papers · 2019: 2 papers · 2020: 5 papers · 2021: 5 papers · 2022: 5 papers · 2023: 5 papers · 2024: 8 papers · 2025: 2 papers · 2026: 4 papers

Papers 50 of 69

  1. Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study. Last author DOI 10.1002/cam4.71490↗
  2. The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic status and therapy-dependent survival in pan… Co-author DOI 10.1016/j.ejca.2025.116189↗
  3. Impact of culture dimensionality and matrix composition on morphology, phenotype and drug response in pancreatic cancer models. Co-author DOI 10.1038/s41598-026-47856-1↗
  4. Technical Recommendation on Multi-Driver Multifrequency MR Elastography for Tomographic Mapping of Abdominal Stiffness With a Focus on the Pancreas and Pancrea… Co-author DOI 10.1097/rli.0000000000001231↗
  5. Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatm… First author DOI 10.1186/s12885-025-13573-7↗
  6. Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids. First author DOI 10.1186/s12935-025-03969-7↗
  7. KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry-based subtyping. Co-author DOI 10.1002/2056-4538.12377↗
  8. Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a… Co-author DOI 10.1016/j.esmoop.2024.103463↗
  9. Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a … Co-author DOI 10.1016/j.esmoop.2024.103705↗
  10. Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Pancreatic Cancer in Germany. Co-author DOI 10.1159/000538171↗
  11. DNA methylation classifier to diagnose pancreatic ductal adenocarcinoma metastases from different anatomical sites. Co-author DOI 10.1186/s13148-024-01768-x↗
  12. Cachexia-Affected Survival Based on Inflammatory Parameters Compared to Complex Conventional Nutritional Assessments in Patients with Pancreatic Cancer and Oth… Last author DOI 10.3390/cancers16061194↗
  13. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Me… Last author DOI 10.3390/cancers16071323↗
  14. 68Ga-labeled fibroblast activation protein inhibitor (FAPI) PET/CT for locally advanced or recurrent pancreatic cancer staging and restaging after chemoradioth… Co-author DOI 10.7150/thno.95329↗
  15. Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised cl… Co-author DOI 10.1016/j.ejca.2022.12.009↗
  16. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. First author DOI 10.1200/jco.22.01134↗
  17. Inflammation-Based Prognostic Scores in Pancreatic Cancer Patients-A Single-Center Analysis of 1294 Patients within the Last Decade. Last author DOI 10.3390/cancers15082367↗
  18. Impact of Smoking, Body Weight, Diabetes, Hypertension and Kidney Dysfunction on Survival in Pancreatic Cancer Patients-A Single Center Analysis of 2323 Patien… Last author DOI 10.3390/jcm12113656↗
  19. Correction: Felsenstein M. et al. Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies? J. Clin. Med. 2022… Co-author DOI 10.3390/jcm12216947↗
  20. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, mu… Co-author DOI 10.1016/j.esmoop.2022.100552↗
  21. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Co-author DOI 10.1038/s41467-021-27088-9↗
  22. Influence of Baseline CT Body Composition Parameters on Survival in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.3390/jcm11092356↗
  23. Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies? Co-author DOI 10.3390/jcm11092367↗
  24. Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The CONKO-008 Phase I Investigation. Last author DOI 10.3390/jcm11164905↗
  25. A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial. Co-author DOI 10.1016/j.ebiom.2021.103327↗
  26. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma -… Co-author DOI 10.1016/j.ejca.2021.03.036↗
  27. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEO… Co-author DOI 10.1016/s2468-1253(20)30330-7↗
  28. Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. Last author DOI 10.3389/fonc.2021.670396↗
  29. Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma-Who Will Benefit from a Secondary Resection? Last author DOI 10.3390/medicina57010077↗
  30. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine i… Co-author DOI 10.1016/j.annonc.2019.09.004↗
  31. Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel a… Co-author DOI 10.1016/j.annonc.2020.05.011↗
  32. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic can… Co-author DOI 10.1016/j.ejca.2020.06.032↗
  33. TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO… Co-author DOI 10.1158/1078-0432.ccr-19-3034↗
  34. Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pan… Last author DOI 10.3390/cancers12113130↗
  35. Split-bolus vs. multiphasic contrast bolus protocol in patients with pancreatic cancer or cholangiocarcinoma. Co-author DOI 10.1016/j.ejrad.2019.07.027↗
  36. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis. Co-author DOI 10.21873/anticanres.13781↗
  37. Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospecti… Co-author DOI 10.1016/j.ejca.2018.06.001↗
  38. Routine portal vein resection for pancreatic adenocarcinoma shows no benefit in overall survival. Co-author DOI 10.1016/j.ejso.2018.05.002↗
  39. The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. Co-author DOI 10.1016/j.suronc.2018.09.004↗
  40. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Co-author DOI 10.1016/s1470-2045(18)30098-6↗
  41. Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-018-0093-y↗
  42. Sequence therapy in metastatic pancreatic cancer. First author DOI 10.1055/a-0581-5640↗
  43. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2017.06.016↗
  44. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based … Co-author DOI 10.1038/bjc.2017.67↗
  45. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Ra… Co-author DOI 10.1200/jco.2017.72.6463↗
  46. Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients. Co-author DOI 10.1371/journal.pone.0186341↗
  47. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. Co-author DOI 10.1016/j.prp.2016.06.001↗
  48. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  49. Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?--Results From the CONKO Study Group. Co-author DOI 10.1097/mpa.0000000000000533↗
  50. Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. Co-author DOI 10.4251/wjgo.v8.i3.248↗

Closest collaborators

The 25 strongest of 163 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marcus Bahra · 34 shared papers, 2012–2026 · strength 3.11
  2. Hanno B. Riess · 32 shared papers, 2011–2024 · strength 2.13
  3. Christopher Neumann · 11 shared papers, 2022–2026 · strength 2.08
  4. Marianne Sinn · 30 shared papers, 2013–2024 · strength 2.08
  5. Thomas Malinka · 11 shared papers, 2018–2026 · strength 1.58
  6. Helmut Oettle · 21 shared papers, 2011–2024 · strength 1.55
  7. Matthäus Felsenstein · 8 shared papers, 2018–2026 · strength 1.44
  8. Jana Käthe Striefler · 19 shared papers, 2013–2022 · strength 1.37
  9. Mihnea Paul Dragomir · 5 shared papers, 2024–2026 · strength 1.06
  10. François Schneider · 5 shared papers, 2023–2026 · strength 1.00
  11. Bruno Valentin Sinn · 12 shared papers, 2013–2024 · strength 0.98
  12. Jens Thomas Siveke · 8 shared papers, 2017–2025 · strength 0.93
  13. Stefan Hubert Boeck · 7 shared papers, 2018–2024 · strength 0.81
  14. Fritz Klein · 11 shared papers, 2012–2021 · strength 0.79
  15. Jens Stieler · 16 shared papers, 2011–2022 · strength 0.78
  16. Hana Algül · 6 shared papers, 2020–2024 · strength 0.71
  17. Katharina Wansch · 3 shared papers, 2025–2026 · strength 0.67
  18. Florian Dölvers · 3 shared papers, 2025–2026 · strength 0.67
  19. Volker Heinemann · 5 shared papers, 2021–2024 · strength 0.64
  20. Uli Fehrenbach · 4 shared papers, 2022–2023 · strength 0.61
  21. Philipp Lohneis · 9 shared papers, 2014–2021 · strength 0.61
  22. Dirk Waldschmidt · 5 shared papers, 2017–2024 · strength 0.58
  23. Carsten Denkert · 9 shared papers, 2013–2021 · strength 0.54
  24. Lea Timmermann · 4 shared papers, 2019–2023 · strength 0.54
  25. Ingo Hartlapp · 4 shared papers, 2021–2024 · strength 0.53

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.